Objective: To evaluate the effects of hyperbaric oxygen solution on hypoxic pulmonary hypertension. Methods: Eleven calves, 2-monthold, 71^6 kg, underwent general anaesthesia, mechanical ventilation and median sternotomy. Catheters for continuous pressure and blood gas measurements were inserted in carotid and femoral arteries, left atrium, right atrium and pulmonary artery (PA), and a flow-probe placed around the PA. After baseline measurements 30 min hypoxic ventilation reduced the mean arterial PO2 from 285^115 to 46^11 mmHg ðP , 0:0001Þ: At this point, without changes in hypoxic ventilation (mean arterial PO2 maintained at 50^5 mmHg), 3 ml/min of hyperbaric aqueous oxygen (AO, oxygen diluted in saline solution) was infused directly into the PA for 30 min, with continuous reading of the monitored parameters. 
Introduction
Pulmonary hypertension can be primary, when no evident cause can be identified, or secondary to a well defined lesion: congenital heart defect with left-to-right shunt and increased pulmonary blood flow, pulmonary venous hypertension, disorders of the respiratory system, hypoxemia, chronic thrombotic and/or embolic disease, and a variety of miscellaneous causes [1, 2] .
While the pulmonary arterial vessels constrict in response to acute hypoxia, prolonged exposure to low oxygen environment leads to structural remodelling of these vessels, including thickness of adventitial and medial layers and muscularization of pre-capillary vessels [3] . The combination of pulmonary vasoconstriction and vascular remodelling, coupled with increased hematocrit, results in pulmonary hypertension and subsequently right ventricular hypertrophy [4, 5] .
In patients with congenital heart defects the severity of the vascular remodelling in the pulmonary vessels appears in direct correlation with the increase of the pulmonary blood flow, the pressure and oxygen saturation at whom it is delivered, and the duration [6] .
Prolonged pulmonary hypertension may result in irreversible vascular lesions, leading to pulmonary vascular obstructive disease and the corresponding clinical pattern of the Eisenmenger syndrome [7 -10] .
It is well recognized that the currently available treatments for pulmonary hypertension, including continuous oxygen administration and vasodilator therapy with either Calcium antagonists, Prostaglandins and Nitric Oxide, are unsatisfactory, with the exception of specific acute or chronic circumstances [1] .
This experimental study has been designed to test the hypothesis that hypoxic pulmonary hypertension can be reduced by delivering hyperbaric oxygen solution directly into the pulmonary circulation.
Materials and methods
After induction of general anesthesia eleven calves, 2 month old, 71^6 kg, underwent tracheal intubation, mechanical ventilation and chest opening through median sternotomy.
Catheters for continuous pressure and blood gas measurements were directly inserted in carotid and femoral arteries, left atrium, right atrium and pulmonary artery, and a flowprobe was placed around the main pulmonary artery (Fig. 1) . The presence of intra-cardiac shunts as well as of patent ductus arteriosus was ruled out at the beginning of the experiments. After the baseline measurements, hypoxic pulmonary hypertension was obtained through 30 min of hypoxic ventilation, reducing the mean arterial PO2 from 285^115 to 46^11 mmHg ðP , 0:0001Þ:
At this point, without any change in the hypoxic ventilation (the mean arterial PO2 was maintained at 50^5 mmHg, NS), 3 ml/min of hyperbaric aqueous oxygen (AO, oxygen diluted in saline solution with a concentration of 0.82 ml of oxygen/ml Lactated Ringer's solution, TherOx Inc., Irvine, California) were added to 72 ml/min of blood withdrawn from the carotid artery and, via a custom syringe pump (TherOx Inc., Irvine, California), infused directly into the pulmonary artery ( Fig. 1) for 30 min, with continuous reading of the monitored parameters.
At the end of the 30 min with AO infusion (Fig. 2 ), after new samples for blood gases were taken and all Student's t-test has been used for statistical evaluation. Data are expressed as mean^SD. The significance level was P ¼ 0:05:
Results
In all experiments 30 min of hypoxic ventilation raised significantly the values of systolic, diastolic and mean pulmonary artery pressure, pulmonary artery/systemic pressure ratio for systolic and mean pressures and pulmonary vascular resistance, while the pulmonary blood flow decreased (Table 1) .
After other 30 min of the same hypoxic ventilation, but with AO infusion, all the values obtained with hypoxic ventilation only (systolic, diastolic and mean pulmonary artery pressure, pulmonary artery/systemic pressure ratio for systolic and mean pressures and pulmonary vascular resistance) returned to be not statistically different from baseline values obtained without hypoxia ( Table 1) .
The pulmonary vascular resistance with AO decreased to a value lower than with hypoxic ventilation only (3.42^0.31 vs 6.89^0.87 U/m 2 , P , 0:0001Þ; but remained higher than the value obtained with normal ventilation (2.67^0.38 U/m 2 , P , 0:01Þ (Table 1) .
Discussion
Oxygen administration by ventilation either may fail to correct arterial hypoxemia with the associated pulmonary hypertension or may be limited by the potential for pulmonary toxicity at high inspired oxygen concentration [11] .
The only possibility currently available for introducing oxygen into blood requires its diffusion across an artificial gas -liquid interface. Mass transport of oxygen by diffusion is inherently slow, so that a relatively large surface area for contact of the two phases is required in both the extracorporeal and intravascular oxygenators [12] [13] [14] . Therefore such devices are inherently bulky, and prolonged contact with blood over a broad surface area may be associated with a variety of complications [15 -16] .
A bubbleless method has been developed for introducing oxygen, dissolved at elevated partial pressures in physiological crystalloid solutions (Aqueous Oxygen, TherOx Inc., Irvine, California), at rapid velocity through capillary tubes in vitro into host liquids at ambient pressure [17] , Aqueous Oxygen is a recently discovered liquid phase combination of water and medical grade oxygen that can be mixed with blood at ambient pressure to correct hypoxemia or produce hyperoxemia with a small amount of carrier solution [18] .
Intravascular administration of hyperbaric oxygen during myocardial reperfusion has been shown to reduce the myocardial injury associated with ischemia/reperfusion in both experimental [19 -21] and clinical studies [22 -23] . Recently intravascular administration of hyperbaric oxygen has been successfully proved also as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model [24] .
In this experimental study the administration of hyperbaric oxygen solution directly into the pulmonary circulation, despite the minimal amount utilized (3 ml/min mixed with 2.7^0.4 l/min of pulmonary blood flow measured during the hypoxic ventilation), allowed for the correction of all the hemodynamic parameters negatively affected by the hypoxic ventilation, with return to the values obtained at baseline with normal ventilation.
Our experimental observations are consistent with our hypothesis that a minimal amount of oxygen is sufficient to reverse the pulmonary vasoconstriction induced by severe hypoxia, provided that the oxygen is administered directly into the pulmonary circulation. Of course we are aware that the amount of 3 ml/min used in our study could represent a substantial volume overload where applied to a subject with a much smaller body weight and size. In view of potential clinical applications in a subject like line a neonate or a small infant, one or more of the currently available solutions to reduce the volume overload should be taken into consideration.
Study limitations
(a) Only the acute effects of AO administration have been studied, in an acute situation with pulmonary hypertension artificially created with 30 min of hypoxic ventilation. The consequences of AO administration after induction of chronic hypoxia [4] or in the presence of established pulmonary hypertension with histological pulmonary vascular lesions [6] should be evaluated. (b) Despite the evident experimental benefits of AO administration on the hemodynamic parameters, reactive oxygen species generation upon the intravascular introduction of oxygen remains a potential concern. Despite the relationship between oxygen partial pressure in the reperfused tissues and reactive oxygen species production is likely to be quite complex, nevertheless it is possible that oxygen toxicity may occur with longer periods of treatment.
Conclusions
Our experimental study demonstrated that acute infusion of hyperbaric AO solution into the pulmonary circulation can completely reverse the negative hemodynamic effects of acute hypoxia. These observations can lead to the extension of the experimental studies with the AO utilization in more severe and chronic situations, in order to evaluate the potential clinical applications of this new available technology. 'If the results observed with acute hypoxia will be confirmed in a chronic hypoxic model, the potential clinical application of administering the hyperoxic solution into the pulmonary circulation through a simple central venous line could be taken into consideration'.
